Regeneron Pharmaceuticals (REGN)

Mar 28, 2025, 2:00 AM EDT - 3 days ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

SNY

Mar 28, 2025, 2:00 AM EDT - 3 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Mar 25, 2025, 4:05 PM EDT - 6 days ago

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Mar 24, 2025, 11:13 PM EDT - 6 days ago

Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

Mar 14, 2025, 9:40 AM EDT - 17 days ago

Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?

Mar 11, 2025, 10:50 PM EDT - 19 days ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Mar 11, 2025, 9:32 PM EDT - 19 days ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Mar 11, 2025, 10:25 AM EDT - 20 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript

Mar 8, 2025, 1:00 PM EST - 23 days ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

SNY

Mar 8, 2025, 1:00 PM EST - 23 days ago

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Mar 6, 2025, 1:53 PM EST - 25 days ago

Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman

Mar 5, 2025, 9:15 PM EST - 25 days ago

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman

Mar 5, 2025, 10:39 AM EST - 26 days ago

Inclusion Body Myositis Pipeline Market Landscape Report 2025 Featuring Abcuro, Regeneron Pharmaceuticals, and Vandria

Mar 4, 2025, 2:11 PM EST - 27 days ago

Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)

Mar 3, 2025, 9:30 AM EST - 4 weeks ago

NASDAQ:REGN Lawsuit Notice: Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Should Contact the Shareholders Foundation

Mar 3, 2025, 8:40 AM EST - 4 weeks ago

DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025

Mar 3, 2025, 5:45 AM EST - 4 weeks ago

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN

Mar 2, 2025, 1:11 PM EST - 4 weeks ago

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman

Feb 28, 2025, 7:00 AM EST - 4 weeks ago

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Feb 27, 2025, 10:06 AM EST - 4 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Feb 26, 2025, 7:00 AM EST - 4 weeks ago

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

Feb 24, 2025, 4:22 PM EST - 5 weeks ago

Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts– Hagens Berman

Feb 24, 2025, 3:10 PM EST - 5 weeks ago

Regeneron's gene therapy study shows improved hearing in children with congenital deafness

Feb 24, 2025, 3:00 PM EST - 5 weeks ago

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

Feb 18, 2025, 7:53 PM EST - 5 weeks ago

REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Feb 18, 2025, 12:59 AM EST - 5 weeks ago

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Feb 16, 2025, 9:54 PM EST - 6 weeks ago

Why Regeneron's Price May Soon Break Out

Feb 16, 2025, 9:39 AM EST - 6 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals